Overall verdict
Neutral
6.3/10
1-year performance
+53.91%
Score breakdown
Up 53.9% over 1 year, 90% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Growth 2.6/10.
23 analysts, target +0.0% vs the price.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures ;
instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies ; breast aesthetics and reconstruction ; contact lenses under the ACUVUE brand ; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Nyse
United States
CEO
Joaquin Duato
Founded
1886
Employees
140 800
Revenue / employee
668 878 USD
Next earnings
October 13, 2026
Institutional holders
- BlackRock, Inc.8.84%
- VANGUARD CAPITAL MANAGEMENT LLC6.56%
- STATE STREET CORP5.58%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.68%
- GEODE CAPITAL MANAGEMENT, LLC2.46%
- JPMORGAN CHASE & CO2.43%
- MORGAN STANLEY1.87%
- NORGES BANK1.33%
- STATE FARM MUTUAL AUTOMOBILE INSURANCE CO1.32%
- Other institutions41.87%
- Rest of the register25.06%
4674 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
281.07 USD
52-week low
175.91 USD
1-year performance
53.91%
Rising
Year-to-date performance
30.15%
Rising
Drawdown
-3.76%
Near its high
Position in the 52-week range
90% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 1.3 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Johnson & Johnson | 89 951 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 1.3 times as much as the world ETF.
- Worst fall:-26 % between February 2020 and March 2020. 10,000 € placed at the top fell to 7 429 €. The world ETF, at worst: -34 %. Back to its high in 1 months.
Johnson & Johnson earned more than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Johnson & Johnson: 89 951 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 196.70 USD - 198.81 USD (2 methods agree)
The price implies growth of 9.93% per year; the company grows at 14.90%.
Gross margin 68.0%, net margin 21.5%, ROIC 17.5%, ROE 25.7%.
Net margin
21.48%
Exceptional
Sector 9.43%|S&P 12.97%
Gross margin
68.03%
Exceptional
Return on equity (ROE)
25.74%
Exceptional
Sector 6.16%|S&P 16.52%
Return on invested capital (ROIC)
17.53%
Exceptional
Free cash flow margin (FCF)
22.71%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.06x
High
Margin stability
9.6 pts
Uneven
Revenue to net income
Growth
2.6/10Revenue up 6.6% over 1 year, 2.7% a year over 5, EPS 14.9% a year over 5.
Revenue (trailing 12 months)
97.9Md USD
Revenue growth (1y)
6.64%
Solid
Revenue growth (3y)
17.63%
Solid
EPS growth (1y)
-0.92%
Declining
EPS CAGR (5y)
14.90%
Exceptional
EPS revisions (3 months)
-4.32%
Revised down
Valuation
2.8/10P/E 31.4x, forward P/E 30.1x, EV/EBITDA 19.6x, PEG 2.10. The multiple sits in the 70th percentile of its own 5-year history.
P/E (TTM)
31.4x
Fair
Sector 27.3x|S&P 23.0x
Forward P/E
30.1x
Very expensive
EV / EBITDA
19.6x
Expensive
Sector 16.0x|S&P 14.5x
PEG
2.10
Very expensive
Sector 1.05|S&P 0.86
Fair value (reverse DCF)
197.76 USD
Overvalued
P/E vs its own 5-year history
among the 30% highest valuations
Pricier than usual
Market cap
649Md USD
Financial strength
8.8/10Cash covers 42.3% of the debt, net debt/EBITDA 0.9x.
Net debt / EBITDA
0.9x
Solid
Gearing (net debt / equity)
33.28%
Solid
Cash
20.8Md USD
Cash / market cap
3.20%
Tight
Cash / total debt
42.33%
Solid
Interest coverage
21.5x
Very solid
Net debt
28.3Md USD
Equity
85.0Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 270.68 USD
- MM20269.37
- MM50264.54
- MM200239.98
- RSI 1455.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+3.14%
200-day average slope, 3 months
+10.61%
50-day average slope, 1 month
+3.27%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.00 % per day
Volatility change
-23.31%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 8.99 (1) | 11.07 (6) | 101 221 (6) | 36 160 (1) | 21 967 (4) |
| 2027 | 10.78 (1) | 12.14 (5) | 108 721 (5) | 37 470 (1) | 24 463 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 23, 2026.
Same sub-industry: 509 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BMY | 7.2 | 7.8 | 125Md USD | 13.5x | 18.9 % | 5.8 % | 14.3 % | 1.9x | 9.2 % | 37.4 % | ||
| 2 | LLY | 6.7 | 6.0 | 1.1T USD | 39.1x | 33.5 % | 47.7 % | 39.8 % | 1.2x | 1.7 % | 58.4 % | ||
| 3 | NOVO B | 6.6 | 7.4 | 170Md USD | 9.5x | 35.3 % | 2.1 % | 38.9 % | 0.7x | 6.7 % | -32.6 % | ||
| 4 | JNJ | 6.3 | 5.5 | 649Md USD | 31.4x | 21.5 % | 6.6 % | 17.5 % | 0.9x | 3.4 % | 53.9 % | ||
| 5 | NOVN | 6.3 | 6.2 | 261Md USD | 22.6x | 23.3 % | -2.0 % | 17.2 % | 1.0x | 6.3 % | 22.0 % | ||
| 6 | ROP | 6.1 | 5.7 | 352Md USD | 23.7x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 5.2 % | 35.9 % | ||
| 7 | AZN | 5.8 | 6.5 | 255Md USD | 24.8x | 17.0 % | 5.8 % | 14.3 % | 1.2x | 4.2 % | 10.7 % | ||
| 8 | MRK | 5.0 | 4.4 | 365Md USD | 118.4x | 4.8 % | 4.9 % | 3.6 % | 1.2x | 4.4 % | 85.2 % | ||
| 9 | PFE | 4.9 | 4.6 | 161Md USD | 37.3x | 6.8 % | 2.6 % | 3.0 % | 2.3x | 6.8 % | 17.5 % |
